- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02750618
Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)
April 11, 2023 updated by: Kyowa Kirin, Inc.
An Open-Label, Phase 2 Study to Assess the Safety, Pharmacodynamics, and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)
The primary objectives of the study are to:
- Establish the safety profile of KRN23 for the treatment of XLH in children between 1 and 4 years old
- Determine the PD effects of KRN23 treatment on serum phosphorus and other PD markers that reflect the status of phosphate homeostasis in children between 1 and 4 years old with XLH
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
13
Phase
- Phase 2
Expanded Access
Available outside the clinical trial.
See expanded access record.
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale University School Of Medicine
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University School of Medicine
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Shriners Hospital for Children
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 4 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female, aged ≥1 year and <5 years
Diagnosis of XLH supported by ONE or more of the following
- Confirmed phosphate regulating gene with homology to endopeptidases located on the X chromosome (PHEX) mutation in the patient or a directly related family member with appropriate X-linked inheritance
- Serum fibroblast growth factor 23 (FGF23) level > 30 pg/mL by Kainos assay
Biochemical findings associated with XLH including:
- Serum phosphorus < 3.0 mg/dL (0.97 mmol/L)
- Serum creatinine within age-adjusted normal range
- Radiographic evidence of rickets
- Willing to provide access to prior medical records for the collection of historical growth, biochemical, and radiographic data and disease history
- Provide written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to any research-related procedures
- Must, in the opinion of the investigator, be willing and able to complete all aspects of the study, adhere to the study visit schedule, and comply with the assessments
Exclusion Criteria:
- Unwilling to stop treatment with oral phosphate and/or pharmacologic vitamin D metabolite or analog (e.g. calcitriol, alfacalcidol) during the screening period and for the duration of the study
- Presence of nephrocalcinosis on renal ultrasound grade 4 based on the following scale: 0 = Normal, 1 = Faint hyperechogenic rim around the medullary pyramids, 2 = More intense echogenic rim with echoes faintly filling the entire pyramid, 3 = Uniformly intense echoes throughout the pyramid, 4 = Stone formation: solitary focus of echoes at the tip of the pyramid
- Planned or recommended orthopedic surgery including staples, 8-plates or osteotomy, within the clinical trial period
- Hypocalcemia or hypercalcemia, defined as serum calcium levels outside the age-adjusted normal limits
- Presence or history of any condition that, in the view of the investigator, places the subject at high risk of poor treatment compliance or of not completing the study
- Presence of a concurrent disease or condition that would interfere with study participation or affect safety
- History of recurrent infection or predisposition to infection, or of known immunodeficiency
- Use of any investigational product or investigational medical device within 30 days prior to screening, or requirement for any investigational agent prior to completion of all scheduled study assessments
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Burosumab Q2W
Burosumab subcutaneous (SC) injections every 2 weeks (Q2W) for a total of 160 weeks.
|
solution for subcutaneous injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline at Week 40 in Serum Phosphorus
Time Frame: Baseline, Week 40
|
The Generalized Estimation Equation (GEE) model includes the change from baseline as the dependent variable, time as the categorical variable and adjusted for baseline measurement, with exchangeable covariance structure.
|
Baseline, Week 40
|
Number of Participants With Adverse Events (AEs), Treatment Emergent AEs (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation
Time Frame: From first dose of study drug through the end of the study (Week 160). Maximum duration of exposure to study drug was 160 weeks.
|
An AE was defined as any untoward medical occurrence associated with the use of a drug, whether or not considered drug related.
A serious AE was defined as an AE that at any dose, in the view of either the Investigator or Sponsor, results in any of the following outcomes: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or disability, a congenital anomaly/birth defect, or other important medical events (according to the investigator).
An AE was considered a TEAE if it occurred on or after the first dose and was not present prior to the first dose, or it was present prior to the first dose but increased in severity during the study.
Events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0: grade 1 (mild), grade 2 (moderate), grade 3 (severe), grade 4 (life-threatening), grade 5 (death).
|
From first dose of study drug through the end of the study (Week 160). Maximum duration of exposure to study drug was 160 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Radiographic Global Impression of Change (RGI-C) Score at Week 40
Time Frame: Week 40
|
Changes in the severity of rickets and bowing were assessed centrally by three independent pediatric radiologists contracted by a central imaging facility using a disease specific qualitative RGI-C scoring system.
The RGI-C is a seven point ordinal scale with possible values: +3 = very much better (complete or near complete healing of rickets), +2 = much better (substantial healing of rickets), +1 = minimally better (i.e., minimal healing of rickets), 0 = unchanged, -1 = minimally worse (minimal worsening of rickets), -2 = much worse (moderate worsening of rickets), -3 = very much worse (severe worsening of rickets).
The Analysis of Covariance (ANCOVA) model includes the RGI-C score as the dependent variable, age and RSS at baseline as covariates.
|
Week 40
|
RGI-C Score at Week 64
Time Frame: Week 64
|
Changes in the severity of rickets and bowing were assessed centrally by three independent pediatric radiologists contracted by a central imaging facility using a disease specific qualitative RGI-C scoring system.
The RGI-C is a seven point ordinal scale with possible values: +3 = very much better (complete or near complete healing of rickets), +2 = much better (substantial healing of rickets), +1 = minimally better (i.e., minimal healing of rickets), 0 = unchanged, -1 = minimally worse (minimal worsening of rickets), -2 = much worse (moderate worsening of rickets), -3 = very much worse (severe worsening of rickets).
The GEE model includes the RGI-C score as the dependent variable, visit as a factor, age and RSS at baseline as covariates, with exchangeable covariance structure.
|
Week 64
|
Change From Baseline in Rickets at Week 40 as Assessed by the RSS Total Score
Time Frame: Baseline, Week 40
|
The RSS system is a 10-point radiographic scoring method that was developed to assess the severity of nutritional rickets in the wrists and knees based on the degree of metaphyseal fraying, cupping, and the proportion of the growth plate affected.
Scores are assigned for the unilateral wrist and knee X-rays deemed by the rater to be the more severe of the bilateral images.
The maximum total score on the RSS is 10 points and the minimum score is 0, with a total possible score of 4 points for the wrists and 6 points for the knees.
Higher scores indicate greater rickets severity.The ANCOVA model includes the RGI-C score as the dependent variable, age and RSS at baseline as covariates.
|
Baseline, Week 40
|
Change From Baseline in Rickets at Week 64 as Assessed by the RSS Total Score
Time Frame: Baseline, Week 64
|
The RSS system is a 10-point radiographic scoring method that was developed to assess the severity of nutritional rickets in the wrists and knees based on the degree of metaphyseal fraying, cupping, and the proportion of the growth plate affected.
Scores are assigned for the unilateral wrist and knee X-rays deemed by the rater to be the more severe of the bilateral images.
The maximum total score on the RSS is 10 points, with a total possible score of 4 points for the wrists and 6 points for the knees.
Higher scores indicate greater rickets severity.
The GEE model includes the change from baseline in RSS as the dependent variable, visit as a factor, age and RSS at baseline as covariates, with exchangeable covariance structure.
|
Baseline, Week 64
|
RGI-C Lower Limb Deformity Score at Week 40
Time Frame: Week 40
|
Changes in the severity of lower extremity skeletal abnormalities were assessed centrally by three independent pediatric radiologists contracted by a central imaging facility using a disease specific qualitative RGI-C scoring system.
The RGI-C is a seven point ordinal scale with possible values: +3 = very much better (complete or near complete healing of rickets), +2 = much better (substantial healing of rickets), +1 = minimally better (i.e., minimal healing of rickets), 0 = unchanged, -1 = minimally worse (minimal worsening of rickets), -2 = much worse (moderate worsening of rickets), -3 = very much worse (severe worsening of rickets).
The ANCOVA model includes the RGI-C score as the dependent variable, age and RSS at baseline as covariates.
|
Week 40
|
RGI-C Lower Limb Deformity Score at Week 64
Time Frame: Week 64
|
Changes in the severity of lower extremity skeletal abnormalities were assessed centrally by three independent pediatric radiologists contracted by a central imaging facility using a disease specific qualitative RGI-C scoring system.
The RGI-C is a seven point ordinal scale with possible values: +3 = very much better (complete or near complete healing of rickets), +2 = much better (substantial healing of rickets), +1 = minimally better (i.e., minimal healing of rickets), 0 = unchanged, -1 = minimally worse (minimal worsening of rickets), -2 = much worse (moderate worsening of rickets), -3 = very much worse (severe worsening of rickets).
The GEE model includes the RGI-C score as the dependent variable, visit as a factor, age and RSS at baseline as covariates, with exchangeable covariance structure.
|
Week 64
|
Change From Baseline Over Time in Recumbent Length/Standing Height
Time Frame: Baseline, Weeks 12, 24, 40, 64, 88, 112, 136, 160
|
Baseline, Weeks 12, 24, 40, 64, 88, 112, 136, 160
|
|
Change From Baseline Over Time in Recumbent Length/Standing Height as Assessed by Height-for-Age Z-Scores
Time Frame: Baseline, Weeks 12, 24, 40, 64, 88, 112, 136, 160
|
Recumbent length/Standing height z scores are measures of height adjusted for a child's age and sex.
The Z-score indicates the number of standard deviations away from a reference population (from the CDC growth charts) in the same age range and with the same sex.
A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher.
Higher Z-scores indicate a better outcome.
|
Baseline, Weeks 12, 24, 40, 64, 88, 112, 136, 160
|
Change From Baseline Over Time in Recumbent Length/Standing Height as Assessed by Percentiles
Time Frame: Baseline, Weeks 12, 24, 40, 64, 88, 112, 136, 160
|
Baseline, Weeks 12, 24, 40, 64, 88, 112, 136, 160
|
|
Change From Baseline Over Time in Serum Alkaline Phosphatase (ALP)
Time Frame: Baseline, Weeks 4, 12, 20, 40, 48, 56, 64, 76, 88, 100, 112, 124, 136, 148, 160
|
The GEE model includes the change from baseline as the dependent variable, time as the categorical variable and adjusted for baseline measurement, with exchangeable covariance structure.
|
Baseline, Weeks 4, 12, 20, 40, 48, 56, 64, 76, 88, 100, 112, 124, 136, 148, 160
|
Percent Change From Baseline Over Time in Serum ALP
Time Frame: Baseline, Weeks 4, 12, 20, 40, 48, 56, 64, 76, 88, 100, 112, 124, 136, 148, 160
|
Baseline, Weeks 4, 12, 20, 40, 48, 56, 64, 76, 88, 100, 112, 124, 136, 148, 160
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Mao M, Carpenter TO, Whyte MP, Skrinar A, Chen CY, San Martin J, Rogol AD. Growth Curves for Children with X-linked Hypophosphatemia. J Clin Endocrinol Metab. 2020 Oct 1;105(10):3243-9. doi: 10.1210/clinem/dgaa495.
- Whyte MP, Carpenter TO, Gottesman GS, Mao M, Skrinar A, San Martin J, Imel EA. Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol. 2019 Mar;7(3):189-199. doi: 10.1016/S2213-8587(18)30338-3. Epub 2019 Jan 9.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 5, 2016
Primary Completion (Actual)
April 20, 2017
Study Completion (Actual)
September 10, 2019
Study Registration Dates
First Submitted
December 6, 2015
First Submitted That Met QC Criteria
April 20, 2016
First Posted (Estimate)
April 25, 2016
Study Record Updates
Last Update Posted (Actual)
April 12, 2023
Last Update Submitted That Met QC Criteria
April 11, 2023
Last Verified
March 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Kidney Diseases
- Urologic Diseases
- Nutrition Disorders
- Genetic Diseases, Inborn
- Musculoskeletal Diseases
- Avitaminosis
- Deficiency Diseases
- Malnutrition
- Bone Diseases
- Metabolism, Inborn Errors
- Bone Diseases, Metabolic
- Renal Tubular Transport, Inborn Errors
- Calcium Metabolism Disorders
- Metal Metabolism, Inborn Errors
- Phosphorus Metabolism Disorders
- Rickets
- Vitamin D Deficiency
- Rickets, Hypophosphatemic
- Hypophosphatemia, Familial
- Familial Hypophosphatemic Rickets
- Hypophosphatemia
Other Study ID Numbers
- UX023-CL205
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on X-Linked Hypophosphatemia
-
Kyowa Kirin Co., Ltd.Active, not recruiting
-
Yale UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedHypophosphatemic Rickets, X Linked DominantUnited States
-
Kyowa Kirin, Inc.Kyowa Kirin Co., Ltd.CompletedX-Linked HypophosphatemiaUnited States
-
Kyowa Kirin Co., Ltd.Active, not recruitingX-linked Hypophosphatemia (XLH)China
-
Kyowa Kirin Pharmaceutical Development LtdActive, not recruitingX-Linked HypophosphatemiaSpain, Italy, United Kingdom, France, Belgium, Denmark, Germany, Hungary, Portugal, Norway, Switzerland, Israel, Netherlands, Czechia, Bulgaria, Sweden, Slovenia, Ireland, Latvia, Slovakia
-
Kyowa Kirin Pharmaceutical Development LtdRecruitingX-Linked HypophosphatemiaFrance, Netherlands, United Kingdom
-
Kyowa Kirin, Inc.Kyowa Kirin Co., Ltd.CompletedX-Linked HypophosphatemiaKorea, Republic of, Canada, United States, Australia, Japan, United Kingdom, Sweden
-
Kyowa Kirin Co., Ltd.Active, not recruitingX-linked Hypophosphatemia (XLH)China
-
Wuerzburg University HospitalKyowa Kirin, Inc.Active, not recruiting
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingX-linked Hypophosphatemia (XLH)
Clinical Trials on Burosumab
-
Kyowa Kirin Pharmaceutical Development LtdRecruitingX-Linked HypophosphatemiaFrance, Netherlands, United Kingdom
-
Wuerzburg University HospitalKyowa Kirin, Inc.Completed
-
Redwood Dermatology SciencesUltragenyx Pharmaceutical IncCompletedPain, Chronic | Hypophosphatemia | Hypophosphatemic RicketsUnited States
-
Ultragenyx Pharmaceutical IncKyowa Kirin Co., Ltd.AvailableX-linked Hypophosphatemia | Tumor-Induced Osteomalacia
-
Bicetre HospitalUnknownRare Diseases | X-linked HypophosphatemiaFrance
-
National Institute of Dental and Craniofacial Research...Active, not recruitingFibrous Dysplasia Of BoneUnited States
-
Laura TosiChildren's National Research Institute; Ultragenyx Pharmaceutical IncActive, not recruitingCutaneous Skeletal Hypophosphatemia Syndrome (CSHS) | Epidermal Nevus SyndromeUnited States
-
Kyowa Kirin Pharmaceutical Development LtdCompletedX-linked HypophosphatemiaUnited Kingdom, France, Ireland, Italy
-
Kyowa Kirin, Inc.Kyowa Kirin Co., Ltd.CompletedX-Linked HypophosphatemiaUnited States
-
Kyowa Kirin Pharmaceutical Development LtdActive, not recruitingX-linked Hypophosphatemia (XLH)Sweden, Spain, United Kingdom, Italy, Austria, France